Skip to main content
. Author manuscript; available in PMC: 2019 Apr 4.
Published in final edited form as: Mucosal Immunol. 2018 Jun 15;11(5):1408–1419. doi: 10.1038/s41385-018-0049-9

Fig. 5.

Fig. 5

PGD2 and LTE4 promote type 2 cytokine production in cultured Tc2 cells. a, b mRNA levels by qPRC in Tc2 cells (a) and protein levels by ELISA in the cell supernatants (b) for IL-5 and IL-13 after treatment with various concentration of PGD2 and LTE4. c Half maximal effective concentration (EC50) of PGD2 or LTE4 for IL-13 production in Tc2 cells compared with that in Th2 cells. d, e mRNA levels in Tc2 cells measured by qPCR (d) and protein levels in the cell supernatants measured by Luminex (e) for type 2 cytokines after treatment with PGD2 and LTE4 alone or their combination. The mRNA levels in control samples were treated as 1-fold. f Increase of IL5- and IL13-mRNA positive Tc2 cells after treatment with PGD2 and LTE4 alone or their combination detected by using PrimeFlow RNA assay. *p < 0.05, **p < 0.005, ***p < 0.001 (n=3 for a-c and f; n=6 for d and e).